Physician profile
Robert I Danoff
NPI 1194898965
$3,945.76
in general payments reported to CMS, 2019-2025
22 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $190 · 2021: $614 · 2022: $441 · 2023: $89.46 · 2024: $642 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,048.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $912.37 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $514.38 | 2019-2022 | |
| Lilly USA, LLC | $482.39 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $397.74 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $378.22 | 2021-2025 | |
| Amgen INC. | $166.10 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $151.86 | 2024-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $148.13 | 2019-2021 | |
| Abbvie INC. | $144.38 | 2021-2025 | |
| Glaxosmithkline, LLC. | $129.35 | 2019-2025 | Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $99.48 | 2022 | |
| Medtronic, INC. | $91.65 | 2024 | Interstim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.14 | 2019-2021 | |
| Exact Sciences Corporation | $72.79 | 2024-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $40.98 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $28.59 | 2024 | |
| Insulet Corporation | $27.58 | 2025 | Omnipod |
| Genentech USA, INC. | $18.50 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.02 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.44 | 2021 | |
| Amarin Pharma, INC. | $14.24 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Danoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.